News | Radiation Oncology | September 13, 2019

Philips Showcases Integrated Radiation Oncology Portfolio at ASTRO 2019

IntelliSpace Radiation Oncology combines all the steps of the radiotherapy department’s workflow into one platform

Philips Showcases Integrated Radiation Oncology Portfolio at ASTRO 2019

September 13, 2019 — Philips will showcase its integrated radiation oncology portfolio at the American Society of Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago. Visitors to the Philips booth will experience Philips IntelliSpace Radiation Oncology, an intelligent patient management solution to manage complexity, improve efficiency and enable operational excellence in radiotherapy departments. The company will also highlight its Pinnacle Evolution treatment planning software, as well as its broad portfolio of connected oncology solutions designed to help health systems achieve the Quadruple Aim: an improved experience for patients and staff, better health outcomes and a lower cost of care.

As the number of new cancer cases continues to rise, Philips said it is essential that care teams have access to integrated oncology solutions across all phases of oncology care to enable a more precise diagnosis, personalized therapy selection and execution, and better outcomes. Radiotherapy processes in particular can be fragmented and inefficient. By reducing uncertainties along the way, care teams can deliver seamless, targeted therapy for each individual patient.

IntelliSpace Radiation Oncology, the latest addition to Philips’ renewed suite of radiation oncology systems and software, provides a harmonized way of working, integrating applications from partners including MIM Software Inc and Sun Nuclear, and automating workflow to help reduce the amount of time it takes from receiving a patient referral to the start of their treatment. In addition, Philips’ recently launched Radiation Oncology Practice Management, a consultancy service to help radiotherapy departments capitalize on the insights and workflow improvement opportunities presented by the platform.

Philips IntelliSpace Radiation Oncology and Radiation Oncology Practice Management are considered works in progress and are not available for sale.

Read the article "Philips Unveils IntelliSpace Radiation Oncology at ESTRO 2019"

The South West Wales Cancer Centre (SWWCC) in the U.K. is among the first partner sites that will implement Philips IntelliSpace Radiation Oncology and associated practice management solutions. “This new solution should help our patients directly by improving their experience and decreasing their time to treatment,” said Russell Banner, M.D., clinical oncologist and radiotherapy lead at the SWWCC. “Furthermore, it will allow us to manage our workflows within our department, seeing where patients are within the often complex treatment pathways.”

Imaging plays a critical role in understanding tumor characteristics, increasing accuracy of therapy delivery and better assessing patient response to treatment. On-site at ASTRO this year, Philips will feature Pinnacle Evolution, the latest generation of the Philips Pinnacle treatment planning software, as well as several imaging systems, including Philips’ dedicated oncology computed tomography (CT) simulator, Big Bore RT, as well as the Ingenia Elition 3.0T magnetic resonance (MR)-RT and Ambition 1.5T MR-RT systems.

Philips’ radiation oncology portfolio complements the company’s IntelliSpace Precision Medicine oncology solutions portfolio, which integrates diagnostics and therapy selection to drive clinical, operational and financial benefits for healthcare providers. The company's oncology solutions portfolio includes:

  • Oncology Pathways – high-quality, detailed, evidence-based oncology treatment protocols powered by Dana-Farber, allowing clinical users to navigate through the branches of pathways to make clinical decisions and provide treatment plan recommendations, including clinical trials;
  • Oncology Platform – a comprehensive platform for use in multidisciplinary (and molecular) tumor board meetings, which integrates data from hospital information systems across different clinical domains including radiology, pathology and genomics, to enable a detailed view of the patient and care path to facilitate cross-disciplinary collaboration and communication;
  • Pathology – Philips’ IntelliSite Pathology Solution, the first U.S. Food and Drug Administration (FDA)-approved digital pathology solution to be marketed for primary diagnostic use to reduce pressure on pathology services by streamlining workflows and extending collaboration to help increase diagnostic confidence; and
  • Genomics – an end-to-end precision medicine platform that automates pathologists’ workflows through collaboration with oncologists and peers, enabling genomic interpretation and therapy recommendation based on a single, comprehensive patient view, which also includes OncoSignal signaling pathway activity analysis to reveal tumor-driving mechanisms.

For more information: www.usa.philips.com/healthcare

Related Content

News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe...
Research finds that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening

Getty Images

News | Lung Imaging | May 05, 2021
May 5, 2021 — Lung cancer is the third most common cance
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
Despite receiving high radiation doses to their tumors, lung cancer patients treated with technique that spares a large part of the esophagus did not develop severe inflammation of the esophagus

Getty Images

News | Lung Imaging | April 30, 2021
April 30, 2021 — For many patients with localized lung cance...
#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

Getty Images

News | Prostate Cancer | April 30, 2021
April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate canc
A 63-year-old multiple #myeloma patient, with skeletal pain. New #FDG avid axillary #lymphadenopathy 62 days (9 weeks) after second #mRNA #vaccination dose. Image used with permission of the Radiological Society of North America (#RSNA)

A 63-year-old multiple myeloma patient, with skeletal pain. New FDG avid axillary lymphadenopathy 62 days (9 weeks) after second mRNA vaccination dose. Image used with permission of the Radiological Society of North America (RSNA)

Feature | Coronavirus (COVID-19) | April 29, 2021 | By Melinda Taschetta-Millane
A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors can also be safely used for treating patients with multiple metastases.

Image courtesy of Accuray

News | Stereotactic Body Radiation Therapy (SBRT) | April 23, 2021
April 23, 2021 — A phase 1 clinical trial led by investigators at the...